YOLFTbeta
Neurotech International Ltd

Neurotech International Ltd

NTI · AU · Healthcare / Biotechnology

0.02AUD+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close0.02
Open0.02
Day Range0.019 – 0.02
52-Week Range0.01 – 0.029
Volume2.72M
Market Cap19.18M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.01
Dividend Yield0.00%
Beta0.01
50-Day Avg0.0141
200-Day Avg0.0137

About

Neurotech International Limited, a clinical-stage biopharmaceutical development company, focuses on development of solutions for paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy in Australia. The company develops NTI164 to treat autism spectrum disorder, paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections, paediatric acute-onset neuropsychiatric syndrome, and Rett syndrome. It also engages in executing medical research projects; and developing technological devices. The company conducts clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its proprietary cannabis strains. The company has a collaboration with The University of Sydney. Neurotech International Limited was incorporated in 2016 and is based in Melbourne, Australia.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Peter James Lawrence Griffiths B.Sc.
  • Employees0
  • Headquarters55 Collins Street, Melbourne, VIC, Australia, 3000, Australia
  • Websitehttps://neurotechinternational.com

Leadership

  • Mr. Mark DaviesExecutive Chairman
  • Mr. Gerald QuigleyDirector of Public Relations & Non-Executive Director
  • Associate Prof. Carolyn EllawayChief Medical Officer
  • Dr. Bonni Goldstein M.D.Chief Medical Advisor for USA · b. 1964
  • Mr. Peter James Lawrence Griffiths B.Sc.Chief Executive Officer of AAT Research Ltd · b. 1964
  • Ms. Alessandra Marie GauvinCompany Secretary

Financials

Income Statement

Currency: AUD2015-12-312016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Revenue215.23K126.67K88.31K30.05K194.56K77.37K206.14K38.26K5.96K1.96K2.44M-
Growth (%)--41.15%-30.28%-65.98%+547.51%-60.23%+166.45%-81.44%-84.43%-67.06%+124422.72%-
Cost of Revenue114.68K547.81K258.10K87.04K1.35M623.77K444.86K573.48K1.74K7.83K289-
Gross Profit100.55K-421.14K-169.79K-56.99K-1.16M-546.40K-238.72K-535.21K4.21K-5.87K2.44M-
Gross Margin46.72%-332.48%-192.27%-189.67%-595.26%-706.26%-115.80%-1398.81%70.73%-298.88%100.00%-
Operating Expense1.01M1.37M3.72M3.69M1.50M723.52K7.21M3.38M9.02M8.75M13.53M-
Operating Income-907.06K-1.79M-3.89M-3.75M-2.66M-1.27M-7.45M-3.92M-9.02M-8.76M-11.09M-11.33M
Operating Margin-421.44%-1410.62%-4406.90%-12477.76%-1368.59%-1641.44%-3611.72%-10245.33%-151342.34%-446293.79%-453.62%-
EBITDA--1.67M-3.63M-3.44M-4.80M-1.21M-7.43M-3.36M-8.98M-8.24M-10.74M-11.33M
EBITDA Margin--1315.46%-4108.06%-11452.68%-2467.26%-1562.30%-3603.75%-8783.57%-150675.01%-419971.12%-439.20%-
Net Income-839.41K-2.18M-4.03M-3.99M-4.80M-1.71M-7.43M-3.36M-7.79M-5.07M-10.60M-6.54M
Net Income Margin-390.01%-1722.11%-4565.50%-13280.17%-2468.29%-2214.72%-3604.58%-8787.42%-130759.17%-258239.99%-433.60%-
R&D28.44K28.44K243.00K290.13K19.98K5.36M5.36M2.58M6.45M5.25M9.94M9.05M
R&D as % of Total Revenue13.21%22.45%275.16%965.59%10.27%6925.28%2599.06%6738.16%108285.97%267319.87%406.72%-
Interest Expense054.45K40.92K18.62K2.01K423.67K1.71K1.37K----
Interest Expense % of Total Revenue0.00%42.99%46.34%61.96%1.03%547.62%0.83%3.58%----

Balance Sheet

Currency: AUD2015-12-312016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Assets3.28M15.37M4.95M4.61M652.75K80.81K5.01M2.02M5.31M12.21M3.24M2.75M
Total Liabilities1.99M893.12K657.04K375.66K355.33K727.10K1.14M592.98K1.35M314.70K285.74K2.14M
Total Equity1.29M7.54M4.30M4.23M297.41K-646.29K3.86M1.43M3.96M11.90M2.95M611.14K
Cash1.88M6.51M2.64M2.21M474.68K12.36K4.83M1.88M3.01M11.63M3.03M2.39M
Total Debt-385.61K374.81K29.79K126.07K54.20K------
Net Debt--6.13M-2.26M-2.18M-348.61K41.84K-4.83M-1.88M-3.01M-11.63M-3.03M-2.39M

Cash Flow

Currency: AUD2015-12-312016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Operating Cash Flow-851.21K-785.79K-3.12M-3.03M-2.54M-682.83K-2.32M-2.96M-6.32M-4.60M-9.02M-4.22M
Investing Cash Flow-961.51K-626.08K-937.15K-771.02K-3.21K-3.21K-3.21K-3.21K0---
Financing Cash Flow3.70M522.70K5.69M3.39M805.00K220.51K7.13M26.40K9.45M11.19M429.53K3.58M
Capital Expenditure337.50K626.08K46.97K97.84K3.21K3.21K3.21K3.21K54.60M05
Free Cash Flow--1.41M-3.17M-3.12M-2.54M-682.83K-2.32M-2.96M-6.32M-4.60M-9.02M-4.22M
Dividends Paid--4.89M3.13M730.02K7.18M7.13M-----
FCF to OCF-179.68%101.50%103.23%100.00%100.00%100.00%100.11%100.00%100.00%100.00%100.00%
Dividend Paid to FCF---154.35%-100.25%-28.71%-1051.12%-307.82%-----

Earnings

Report DateMar 1, 2017Aug 31, 2017Feb 28, 2018Sep 2, 2018Feb 28, 2019Aug 30, 2019Feb 25, 2020Aug 31, 2020Feb 26, 2021Aug 29, 2021Feb 24, 2022Aug 31, 2022Feb 28, 2023Feb 27, 2025Aug 29, 2025
EPS Estimate0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00
EPS Actual-0.03-0.02-0.02-0.02-0.01-0.03-0.01-0.01-0.01-0.010.000.000.00-0.010.00
Surprise---------------
Timing-----------After-hoursAfter-hours--

Key Statistics & Ratios

Market Cap19.18M
Enterprise Value21.05M
Trailing P/E0.00
Forward P/E0.00
Price / Sales4.05
Price / Book38.34
EPS-0.01
Book Value0.00
Revenue (TTM)4.73M
Gross Profit (TTM)4.73M
EBITDA-6.61M
Profit Margin-138.11%
Operating Margin83308.73%
Return on Equity-366.75%
Return on Assets-138.02%
Shares Outstanding1.32B
Shares Float1.05B
Beta0.01
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Feb 1, 20198:7